Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 11/20 | 0.61 |
| ▸ | NR1H3 | Q13133 | 11/20 | 0.61 |
| ▸ | RORC | P51449 | 1/20 | 0.60 |
| ▸ | MLYCD | O95822 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.48 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.48 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.48 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131990 | 0.91 | NR1H2 (0.68) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| Water SCHEMBL1684070 | 0.88 | NR1H2 (0.65) | NR1H2NR1H3MLYCDSMN1; SMN2AR | |
| SCHEMBL9621271 | 0.83 | NR1H2 (0.60) | NR1H2NR1H3RORCMLYCDSMN1; SMN2 | |
| SCHEMBL8021367 | 0.81 | NR1H2 (0.58) | NR1H2NR1H3RORCMLYCDSMN1; SMN2 | |
| SCHEMBL1516045 | 0.81 | ESR1 (0.61) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL6808538 | 0.81 | ESR1 (0.61) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL17054 | 0.79 | NR1H2 (0.56) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL14593303 | 0.79 | NR1H2 (0.61) | NR1H2NR1H3MLYCDSMN1; SMN2AR | |
| SCHEMBL128398 | 0.79 | NR1H2 (0.56) | NR1H2NR1H3MLYCDSMN1; SMN2 | |
| SCHEMBL24245843 | 0.79 | NR1H2 (0.56) | NR1H2NR1H3MLYCDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023593-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230019681-A1 | POSITIVE RESIST MATERIAL AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023593-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | HNRNPU, EWSR1, HNRNPR | NR1H2 3896/4885NR1H3 3340/4885RORC 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.